Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03-Reference-Cited by-同舟云学术

Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03

Published:2012-09-04 Issue:2 Volume:60 Page:254-257
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr. Blood Cancer

Author:

Escherich Gabriele,Zimmermann Martin,Janka-Schaub Gritta,

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.24273/fullpdf

Reference22 articles.

1. Clinical study of daunomycin (NSC-82151) in children with acute leukemia;Holton;Cancer,1968

2. Clinical study of daunomycin and prednisone for induction of remission in children with advanced leukemia;Holton;N Engl J Med,1969

3. Comparative effect of daunomycin and adriamycin on nucleic acid metabolism in leukemic cells in vitro;Tatsumi;Gann,1974

4. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia;Tan;Cancer,1967

5. Cytotoxicity of adriamycin and daunorubicin for normal and leukemia progenitor cells of man;Buick;J Natl Cancer Inst,1979

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The roles of TPL in hematological malignancies;Hematology;2023-07-04

2. The beneficial role of exercise in preventing doxorubicin-induced cardiotoxicity;Frontiers in Physiology;2023-03-09

3. Theranostic Potentials of Gold Nanomaterials in Hematological Malignancies;Cancers;2022-06-21

4. Reduced Dose Intensity of Daunorubicin During Remission Induction for Low-Risk Patients With Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Chinese Children’s Cancer Group;Frontiers in Oncology;2022-06-07

5. Epifriedelanol enhances adriamycin-induced cytotoxicity towards K562/ADM cells by down regulating of P-gp and MRP2;Xenobiotica;2022-04-03